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Background: Field and community evaluation of the routine usage of CD4 T counting platforms is essential in
resource-poor countries for efficient and cost-effective monitoring of HIV-infected adults and children attending
health care centers.
Methods: We herein addressed the principal issues raised by the implementation of the single-platform, volumetric
Auto40 flow cytometer (Apogee Flow Systems Ltd, Hemel Hempstead, UK) in 8 community HIV monitoring
laboratories of different levels throughout Chad. This is a country with particularly difficult conditions, both in terms
of climate and vast geographical territory, making the decentralization of the therapeutic management of HIV-
infected patients challenging.
Results: The routine usage of the Auto40 flow cytometers for a period of 5 years (2008–2013) confirms the
reliability and robustness of the analyzer for community-based CD4 T cell enumeration in terms of both absolute
numbers and percentages to enable accurate monitoring of HIV-infected adults and children. However, our
observations suggest that the Auto40 mini flow cytometer is not suitable for all laboratories as it is oversized and
ultimately very expensive.
Conclusion: The Chad experience with the Auto40 flow cytometer suggests that its usage in resource-limited
settings should be mainly reserved to reference (level 1) or district (level 2) laboratories, rather than to laboratories
of health care centres (level 3).
Keywords: Flow cytometry, CD4 T cell count, CD45, Decentralization, Sub-Saharan Africa, ChadBackground
The HIV epidemic remains a major global public health
challenge with a total of 34.0 million people living with
HIV worldwide [1]. During the past decade, there has been
a remarkable global effort to improve access to HIV anti-
retroviral therapy (ART). Despite this progress, approxi-
mately half of all people who need treatment are not yet
receiving it. The need for ART is most critical in sub-
Saharan Africa, where less than 40% of eligible patients cur-
rently receive treatment [1,2]. The guidelines of the World
Health Organization (WHO) for the scaling up of ART in
adults and children living in resource-limited settings [3-5]* Correspondence: koyaltad@yahoo.fr
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reproduction in any medium, provided the oremphasize the necessity of laboratory monitoring which is
initially based on immunological assessment by the enu-
meration of CD4 T lymphocytes. This enumeration helps
guide timing of ART initiation and assists in monitoring
immunological responses in patients on ART. In addition,
measurement of the HIV-1 RNA load is now recom-
mended in order to monitor virological responses, identify
early therapeutic failures and assess virological outcomes
following therapeutic switches [6,7].
Affordable CD4 Tcell enumeration has gradually become
possible through the use of simple, compact and robust
low-cost new generation, point-of-care flow cytometers.
These devices operate as single-platform volumetric instru-
ments without the use of expensive microbeads [8-10]. In-
troduced in 2005, the recently developed Auto40 flowLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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UK; www.ApogeeFlow.com) was originally designed for
military applications [11]. The Auto40 assay is based on a
no-lyse procedure [12] which avoids the need for red blood
cell lysis. This, in turn, reduces assay variability due to
changes in assay conditions, such as time and temperature
of incubation, as well as differences in the effects of lysis
reagents on cells following exposure [13]. The Auto40
analyzer uses a volumetric syringe powered by a stepper
motor that draws and delivers a known sample volume.
Therefore, the absolute volumetric counting allows the dir-
ect determination of the number of cells per unit of sample
volume without the need for reference material such
as microbeads [8,14]. The Auto40 analyzer was initially
intended for CD4 T cell enumeration based on primary
CD4 gating and has been validated in Senegal for measure-
ment of absolute CD4 T cell count by reference to the
FACSCount system [11]. The analyzer has been recently
updated for CD4 T cell measurement using a protocol in-
volving primary CD45 gating followed by secondary CD4
gating. The CD45-assisted method for CD4 Tcells enumer-
ation in percentage has been previously demonstrated to
allow accurate CD4 T cell counting, when used in dual
[15-17] as well as single-platforms, either volumetric [18]
or bead-based [19,20]. The updated version of the Auto40
analyzer has been recently validated for the enumeration of
both absolute numbers and percentages of CD4 T cells in
Cameroon [21,22] as well as in Chad [23] and is therefore
addressing the current WHO recommendations for CD4 T
cell measurements in children less than 5 years [5].
The objective of the present study was to assess the per-
formance of the Auto40 CD45-assisted flow cytometer at
the scale of a sub-Saharan African country whereby there
are harsh climatic conditions and challenges in delivering
operational public health programs. Indeed, the conditions
within many community laboratories, where several Auto40
analyzers have been implemented, are not similar to the
conditions within the laboratories in large cities and aca-
demic medical centers where the Auto40 flow cytometer
has been previously evaluated. Such evaluations have oc-
curred in laboratories in Dakar, Senegal [11], Yaoundé,
Cameroon [21,22] and Chad [23]. Furthermore, Chad is a
country with particularly difficult conditions in terms of
both climate and bad infrastructures making the decen-
tralization of the therapeutic management of HIV-infected
patients especially challenging. Therefore, in this study, we
addressed the principal issues raised by 4 years of routine
usage of the Auto40 flow cytometers implemented in 8 HIV
monitoring laboratories of different levels throughout Chad.
Methods
Auto40 flow cytometers installed in Chad
The Auto40 flow cytometers (Apogee Flow Systems Ltd)
installed in Chad are equipped with a green laser at532 nm, a side scatter detector, two fluorescence channels
and means for direct volumetric counting which is does
not require the lysis of red blood cells. In brief, direct
volumetric CD4 T cell measurements are performed on
the Auto40 using phycoerythrin (PE)-conjugated anti-CD4
and PE-Dyomics649-conjugated anti-CD45 monoclonal
antibodies (Apogee Flow Systems Ltd). The Auto40 ana-
lytical procedure avoids the need for a cell washing step.
Thus, 50 μl of whole EDTA-blood is added into polypro-
pylene test tubes containing pre-dispensed, stabilized
monoclonal antibodies. After 25 minutes of incubation at
room temperature in the dark, the blood samples are di-
luted 1:10 in phosphate buffered saline. The non-lysed-
non-washed stained samples are run on the Auto40 flow
cytometer and the CD4 T cell counts are obtained in abso-
lute numbers and in percentages.
The simplified protocol used by the Auto40 flow
cytometer is based on a sequential strategy initially in-
volving gating on the total white blood cell population
(CD45-positive population) which serves as the common
denominator to enumerate CD4-positive T lymphocytes,
instead of primarily gating on the lymphocyte population,
a method which is error-prone [24]. The specific use of
the side scatter parameter allows for the discrimination of
monocytes due to the high side scatter and low CD4
expression of monocytes. This enables for the accurate
enumeration of CD4-positive T cells as they display, in
contrast, to monocytes, low side scatter and high CD4 ex-
pression [15]. The analysis on the Auto40 flow cytometer
is automatically performed by the built-in software “Auto-
lymphocyte” (Apogee Flow Systems Ltd), with the option
of controlling and assessing the quality of the data ana-
lysis. CD45-positive lymphocytes and monocytes are iden-
tified by primary gating on bright CD45 fluorescent cells
in a CD45xside scatter dot plot scattergram (Figure 1A).
The CD45 fluorescent polymorphonuclear cells are ex-
cluded from the gating according to their high nuclear
density. Within the CD45-positive cells, CD4-positive and
CD4-negative lymphocytes are identified by secondary gat-
ings in a CD4xside scatter dot plot scattergram (Figure 1B).
CD4-positive T lymphocytes are easily separated from
monocytes and CD4-negative lymphocytes, and counted
independently. The CD4 T lymphocyte count in absolute
number corresponds to the CD4-positive secondary CD4
gating cell populations. The CD4 T lymphocytes count
in percentage corresponds to the ratio of CD4-positive
lymphocytes count in absolute number to the total CD4-
positive and CD4-negative lymphocytes counts, corre-
sponding to the sum of both secondary CD4 gatings. The
sample lecture takes around 2 minutes. Aside from simpli-
fying the sample preparation, the software “Auto-lympho-
cyte” allows automatic lecture which greatly reduces
manipulations required by laboratory technicians. The
entire procedure is rapid and only requires 30 minutes to
A B
Figure 1 Gating strategy for the volumetric Auto40 flow cytometer (Apogee Flow Systems Ltd, Hemel Hempstead, UK), as depicted
from typical figure provided by “Auto-Lymphocyte” software (Apogee Flow Systems Ltd) for the counting of CD4 T lymphocytes in
one K3-EDTA-anticoagulated blood sample, incubated with phycoerythrin (PE)-conjugated anti-CD4 and PE-Dyomics649-conjugated
anti-CD45 monoclonal antibodies (Apogee Flow Systems Ltd): (A) CD45-PE-Dyomics649 × axis-light scatter dot plot scattergram; the
primary CD45 gating differentiates clearly the CD45-positive lymphocytes and monocyte populations, and the population of
polymorphonuclear cells; (B) CD4-PE × axis-light scatter dot plot scattergram; double secondary CD4 gating allows counting
independently the population of CD4-negative lymphocyte and CD4-positive lymphocytes; the CD4 T lymphocytes count in absolute
number is given by the CD4-positive gating; the CD4 T lymphocytes count in percentage corresponds to the ratio of CD4-positive
lymphocytes count in absolute number to the total CD4-postive and CD4-negative lymphocytes counts, corresponding to the sum of
both secondary gating.
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cytometer has the theoretical capacity to perform 150
CD4 T cell enumerations per day.
Quality control on the Auto40 flow cytometer imple-
mented in Chad is assessed by the use of a calibrated
bead sample (Apogee cat # 1444 for Auto40-green, Apo-
gee Flow Systems Ltd) at the beginning and end of each
session, and on the use of stabilized blood reference
samples (Cytofix CD4, CaltagMedsystems Ltd, UK) as an
additional external control.
The Senegalese validation used the initial Auto40 ver-
sion based on primary CD4 gating and focused exclusively
on CD4 T cell counting in absolute numbers [11]. How-
ever, as the percentage of CD4 T cells is essential for mon-
itoring HIV disease progression in children less than
5 years [3,10], the primary CD4 gating format of the
Auto40 analyzer that only measures absolute CD4 T cell
numbers was modified by the manufacturer in 2006 to
measure the percentage CD4 T cells. Thus, the updated
version of the Auto40 flow cytometer, now based on a
protocol using anti-CD45 and anti-CD4 monoclonal anti-
bodies, is not only valid for CD4 T cell enumeration in ab-
solute number, but also in percentage [21].
Due to the stability of its optical bench, the compact
low-range single-platform Auto40 constitutes is a portable
desk-top flow cytometer that can run on a 12-volt car bat-
tery and can be connected to a laptop computer. Thus,
the Auto40 analyzer can be used in a mobile health care
unit that could make CD4 T cell enumeration available inremote or hard-to-reach locations, as previously shown in
a mobile health unit in Cameroon [22].
Implementation of HIV monitoring laboratories for CD4 T
enumeration by Auto40 flow cytometers in Chad
Chad is a large country with a surface area of 1,284,000 km2.
This country is located within the Sahel, the horizontal
strip of Africa lying between the Sahara Desert in the
North and more fertile regions in the South. Its tropical
climate has two distinct seasons: a wet season from May
to September and a prolonged dry season that is marked
by the harmattan, the hot (temperatures ranging between
22° to 45°C), and dusty winds from the Sahara Desert.
Chad is characterized by a generalized HIV epidemic [25],
with the adult HIV-1 sero-prevalence rate sitting at 3.5%
in 2007 and reaching up to 8% in N’Djamena [1], and the
HIV variants in these regions express high genetic diver-
sity [26]. HIV prevalence in the South is 10% and in the
East it is about 3%. UNAIDS reported that, at the end of
2010, 200,000 individuals from Chad were living with HIV
infection, and 110,000 of those infected were women aged
15 years or older and 19,000 were children [1]. ART is
indicated in greater than 55,000 individuals. Currently, it
is estimated that only 6,500 people have access ART. The
high level of antiretroviral drug resistance in patients on
first-line therapy clearly raises the issue of adequate HIV
laboratory monitoring in Chad [27].
In 2008, the “Conseil National de Lutte contre le
SIDA” in N’Djamena proposed an international tender
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antiretroviral treatment centers in Chad. Therefore, 8
Auto40 flow cytometers (Apogee Flow Systems Ltd) were
acquired at the price of 23,500 € per analyzer for imple-
mentation throughout Chad. Two analyzers were installed
in N’Djamena (at the hôpital Militaire d’Instruction, and
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ventive maintenance.
In addition, six CyFlow (CyFlow SL: 1; CyFlow Coun-
ter: 5; Partec, Muenster, Germany) were acquired at the
price of 17,500 € in 2006 and were implemented in
Abeche, Adre, Biltine, Koumra, Mao and N’Gouri. Five
first-generation FACSCount (Becton Dickinson Biosci-
ences, San Jose, California, USA) analyzers were ac-
quired at the price of 37,000 € in 2003 and have been
installed in N’Djamena, Goz-Beida, Moundou, Pala and
Sahr.
Evaluation of the routine usage of Auto40 flow
cytometers in Chad (2008–2012)
The main characteristics examined to evaluate the perfor-
mances of the 8 Auto40 flow cytometers distributed across
Chad included: i) general characteristics of each laboratory
(location, environment, and level); ii) provision of electri-
city and water; iii) availability of human resources; iv) re-
agents and consumables supplies; v) medical activity and
CD4 T cell enumeration cost at each site; vi) quality assur-
ance and control; vii) instrument support. In addition, an
open questionnaire was performed at each laboratory fo-
cusing on the activity organization, the relations with the
local technical support team and the distributor (Inodia,
France), and more generally on all problems raised involv-
ing the use of Auto40 analyzers in Chad. The study was
approved by the Chad Ministry of Public Health.
Results
The results of the evaluation of the routine usage of the 8
Auto40 flow cytometers implemented in Chad for a period
of 5 years (2008–2013) are shown in Table 1. The imple-
mentation of the Auto40 flow cytometers in the reference
laboratory (level 1) of the hôpital Militaire d’Instruction,
N’Djamena, in the district laboratories (level 2) of Bongor,
Doba and Mongo, and in the health centers laboratories
(level 3) of the Centre d’Appui Psycho-Médico-Social Al-
Nadjma, N’Djamena, and of Kelo, Koumra and Maïssalis,
was urban in N’Djamena and Doba, and rural in the other
sites. Despite very high temperatures and the frequent pre-
sence of dust, analyzers could operate as non-contained
units without air conditioning (except for two laboratories
in N’Djamena and Doba) and with exposure to outdoor
dust in Bongor, Kelo, Maïssana and Mongo, where the la-
boratories were ventilated only by ceiling and floor fans.
Except for the hôpital Militaire d’Instruction in N’Djamena,
where electricity works properly, power outages of electri-
city at the other sites were generally frequent. However,
the frequent breaks of electric current in the majority of
sites did not prevent the use of the Auto40 flow cytometer
which uses electric generators as power substitutes, con-
necting the cytometer in series with an on-line UPS (Un-
interruptible Power Supply). This latter device has a powersupply of 2 KVA and a capacity of one hour, which was suf-
ficient to maintain its use in the laboratory in cases of
power outages. The use of sheath fluid recycling cassette
proposed by the manufacturer for closed use of the Auto40
flow cytometer (as in a military vehicle) was chosen in all
locations outside of the capital. Nevertheless, water was
available in all laboratories where Auto40 cytometers were
installed and there was the possibility of using locally-
distilled water, in addition to the ability to deliver bottled
distilled water to sites where the consumption and general
laboratory activity are low. Furthermore, although trans-
portable, none of the Auto40 instruments in Chad have
been deployed on mobile units, Thus, the use of sheath
fluid recycling cassettes obviously significantly increases
the costs of consumables, since the cassette fluid recycling
drive costs 921 € and it is recommended that the cassette
fluid be changed after 1500 tests, are used in mobile health
care units.
With regards to human resources, it is remarkable that
users of Auto40 flow cytometers in Chad were exclusively
senior laboratory technicians and there was an absence of
biologist involvement in laboratory management at the
survey sites. The reagents used in all sites included the
combination of anti-CD45 and anti-CD4 monoclonal anti-
bodies, thereby enabling for the enumeration of CD4 T
lymphocyte absolute values and percentages, as the CD4
T lymphocyte count in percentage is only recommended
for children between 24 and 59 months according to the
2010-revised WHO [2]. Lyophilized and heat-resistant re-
agents were preferred because of the high environmental
temperatures, and the long distance of some sites from
the capital. The supply of reagents was consistent and
without disruptions. The estimated final cost for a CD4 T
lymphocyte count in absolute value and in percentage was
between 11.0 and 13.4 €. In Chad, this cost was estimated
to be around 16 € for a CD4 T cell count given in absolute
value and percentage obtained with FACSCalibur or
FACSCount (Becton Dickinson), and 10 € with CyFlow
(Partec).
The Auto40 flow cytometers were located in sites that
supported mostly adults, with active files from 41 to 458
patients (mean of 144 patients per site), including a vari-
able number of adults from 33 to 421 (mean of 127 per
site) and a low number of children under 5 years from 2
to 61 (mean of 16 per site). In fact, the number of CD4
T cell enumeration per site was variable, with a mean of
about 360 per year per location. However, some sites
had very low activity, as in Mongo (n=55 in 2011) and
Maïssala (n=62 in 2011).
A general procedure for quality assurance had been
established in each laboratory by the National Executive
Secretariat of the “Conseil National de Lutte contre le
SIDA”, but this was not evaluated, mainly because the
national network of laboratories was not yet operational
Table 1 Main characteristics describing the implementation and the 5 years usage (2008–2013) of 8 single-platform,
volumetric, Auto40 flow cytometers for community-based point-of-care CD4 T lymphocytes enumeration installed
in Chad







Mongo Bongor Kelo Doba Maïssala Koumra
Level of laboratory
facility*
1 3 2 2 3 2 3 3
Laboratory
characteristics
Situation Urban Urban Rural Rural Rural Urban rural Rural
Distance from the
capital city NDJ (km)








22/45 22/45 22/45 20/40 20/40 20/40 20/40 22/40
Air conditioned
(yes/no)





No Yes Yes Yes Yes Yes Yes Yes
Unreliable water
supplies
No No No No No No No No
Human
resources
Biologist (number) No No No No No No No No
Trained technician
(number)






Yes Yes Yes Yes Yes Yes Yes Yes
Reagents delivery Regular Regular Regular Regular Regular Regular Regular Regular
Reagents price (€) 10 10 12 11 11 12 12 12
Sheath fluid recycling
cassette
No No Yes Yes Yes Yes Yes Yes
Number of followed
up patients (in 2012)












(< 5 years) patients
(in 2012)
7 37 2 4 61 5 4 12
Number of CD4 T
cells enumeration**
(in 2011)
341 1156 55 123 559 230 62 358




11.0 11.0 13.0 12.0 12.1 13.1 13.4 13.2
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Yes Yes Yes Yes Yes Yes Yes Yes
Internal quality
control
Yes Yes Yes Yes Yes Yes Yes Yes
International external
quality control









Yes Yes Yes Yes Yes Yes Yes Yes
Troubleshooting No No Yes (electronic
memory card)
No No No No No
*Level 1: Reference laboratory; Level 2: District laboratory; Level 3: Health care center laboratory.
**Results of CD4 T cell enumeration with Auto40 flow cytometer are systematically given in absolute count as well as in percentage.
***The estimated final cost of 1 CD4 T cell enumeration does not take into account the cost of the use of sheath fluid recycling cassette in province laboratories,
as well as the contractual maintenance of the Auto40 flow cytometers by the distributor (Inodia, France).
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control procedures recommended by the manufacturer
were performed, using calibrated beads (for Apogee
Auto40-green). However, there was no registration of
data collection of periodic internal quality control, as
well as no temporal analysis of the obtained values, such
as through the use of the Levy-Jennings approach, for
example. Finally, no national or international external
quality control for CD4 T cells enumeration, including
CD4 monitoring by Auto40 flow cytometry platforms,
were performed in Chad.
Technical support of the 8 Auto40 flow cytometers was
organized as follows in Chad. There was no local distribu-
tor. However, a technician of the “Conseil National de
Lutte contre le SIDA” overaw on-site national analyzers
every 3 months (quarterly), and ensured dust removal,
maintenance and periodic routine maintenance advocated
by the manufacturer. In addition, a maintenance contract
had been provided by Inodia (France), priced at 4500 €
per Auto40 flow cytometer. In four years, such mainten-
ance took place twice in 2011 and 2012. In the event of
the occurrence of the most important technical problems
to the analyzer, such as computer updating or breakdown,
the design engineer of the Auto40 flow cytometer (from
Apogee Flow Systems Ltd.) accompanied Inodia (France)
in Chad at a price of 500 € per day. In total, it is possible
to estimate the mean cost of the contractual maintenance
performed by Inodia (France) at about 2300 € per analyzer
and per year during the 5 years survey period. Note
that all 5 FACSCount (Becton Dickinson) and 6 CyFlow
(Partec) are also currently working properly in Chad. To
our knowledge, a similar maintenance schedule has been
organized in other Africa countries where Auto40 flow
cytometers have been implemented [local distributor ortechnician; on-site maintenance organized by Inodia
(France); specialized mission in case of unresolved issues
organized by Apogee Flow Systems Ltd. (UK), concerning
about 15 analyzers throughout sub-Saharan Africa.
In addition to the commercial service of reagents sup-
ply, and to on-site maintenance of the analyzers, Inodia
(France) has been involved in 2012 in the national train-
ing of biologists and clinicians on the use in clinical
practice of CD4 T lymphocytes count, in relationship
with national health authorities.
Discussion
In the present study, we addressed the principal issues
raised over 5 years of routine usage of the Auto40 flow
cytometers which had been implemented in 8 HIV mon-
itoring laboratories throughout Chad. The installation
and extended usage of a significant number of Auto40
flow cytometers in Chad also allowed us to assess the
performance of these CD4 T cells counters in situations
of actual use, across an entire country with harsh cli-
matic conditions and a large geographical territory. This
field approach is original, and complements the previous
strictly biological evaluations of the analyzers in refer-
ence laboratories in Senegal [11], Cameroon [21,22], as
well as recently in Chad [23].
The analyzers were able to function properly regard-
less of the level of the laboratory, including in level-3 la-
boratories in health centers. They were even able to
function properly in rooms partially exposed to the out-
side environment, which were not air conditioned, which
had widespread dust, and in settings where there were
frequent electricity outages. In each site where an
Auto40 flow cytometer was located, a senior laboratory
technician was able to proficiently replace a biologist, at
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agents and using a simple protocol. Of major interest is
our finding that the A40 technology may be easily
implemented and maintained by technicians. Indeed,
well-trained technicians were able to use the Auto40
flow cytometer with low intra- and inter- run variability
of less than 10% [21,22]. This value was comparable to
other published reports using single-platform flow
cytometers [28,29], and is considered acceptable in rou-
tine clinical practice [29]. A single failure of an electronic
nature occurred in only one analyzer during 5 years of use.
Routine maintenance recommended by the manufacturer
was performed regularly, as was the contractual annual
maintenance by the technician of the distributor arriving
from France. Altogether, these observations of actual use
in tropical conditions confirm the reliability and robustness
of the Auto40 flow cytometer, originally designed for mili-
tary applications [11,21,22].
One of the interesting characteristic features of the
Auto40 analyzer is its use of stabilized monoclonal anti-
bodies. The assay reagents can be stored for prolonged
periods of time (up to 12 months) at high temperature
without any loss of biological activity [30]. The use of
thermo-resistant reagents allowed reliable measurements
of CD4 T cell count, both in terms of absolute numbers
and percentages, under unfavorable conditions such as
high temperatures encountered in the tropics and in
remote areas where cold conditions for the storage of
reagents, particularly during shipment and delivery, are
not guaranteed [31]. The thermo-stable monoclonal an-
tibodies used in the present study can be kept for as
long as one year at room temperature (30°C), and have
been chosen for all laboratories equipped by an Auto40
flow cytometer in Chad. The possibility of long-term
storage of reagents at room temperature for one year
should facilitate the planning of laboratory activities and
reduce the costs related to loss of reagent stability. Over-
all, the use of thermo-stable reagents increases the ac-
cessibility to flow cytometry testing. However, while the
manufacturing costs related to the antibody stabilization
procedure does not exceed 15% of the original cost [30],
the final sale prices of thermo-resistant reagents mar-
keted by Inodia (France) is higher than 40% compared
to those of liquid reagents. In practice, cost reduction on
reagents for CD4 T cell counting could only materialize
with active pressure on manufacturers and likely their
agencies, in order to reduce production, administrative
and logistical expenditures acting to inflate the costs of
laboratory intrants in resource-limited settings.
Some criticisms which do not stricto sensu address the
intrinsic qualities of the Auto40 flow cytometer can never-
theless be made based on the use of the analyzers in Chad.
First, the price of the Auto40 flow cytometer is about 30%
higher than its principal competitors sold in Chad. Thechoice of reagents is also somewhat problematic. Indeed,
if the use of heat-stable reagents is indicated in Chad, the
choice of using monoclonal anti-CD4 and anti-CD45 anti-
bodies as reagents to systematically render the number of
CD4 T cells in both absolute number and percentage ap-
pears unfounded. Indeed, given the percentage is only
recommended in children between 24 and 59 months, its
measurement may not be of interest in individuals over
the age of five years [4]. The choice of routine use of anti-
CD4 and anti-CD45 antibodies doubles the cost of CD4 T
lymphocyte counting. As the number of children repre-
sents less than 15% of followed patients, it may have been
possible in most treatment centers where the number of
treated children is very low to enumerate CD4 T cell abso-
lute numbers exclusively, since the treatment initiation
threshold of 750 CD4 T cells/μl is now recommended by
WHO in children between 24 and 59 months [4,5].
The distribution of Auto40 flow cytometers was also
questionable, given the very low clinical activity at some
sites. Half of the 8 cytometers were installed in sites where
the number of CD4 T measurements performed was less
than 300 per year, despite the fact that each cytometer can
perform 150 tests per day. Only two Auto40 flow
cytometers (in N’Djamena and Kelo) had significant usage,
performing over 500 tests a year. Moreover, the systematic
use of sheath fluid recycling cassettes in provintial sites
appears to have little to no justification as it results in an
obvious increase in cost. Considering the relatively high
costs involved (Auto40 flow cytometers themselves, re-
agents, sheath fluid recycling cassettes, contractual main-
tenance), and the low to very low medical activity in most
sites, it appears that the cost of CD4 T cell enumeration
using Auto40 flow cytometers may be excessive for some
sites.
These observations raise the issue of decentralization of
immunological monitoring in large areas where laborator-
ies are remote. One solution could be to use mobile health
units capable of performing immunological monitoring
of HIV-infected patients [32], as shown recently in
Cameroon [22]. Another option could be to send blood
samples, possibly with a blood preservative [33], to a refer-
ence or district laboratory equipped with a CD4 T cell
counter. The lack of external quality control program-
mers, such as those proposed for resource-limited settings
by QASI [34,35] or AFREQAS [36], is another flaw and
likely stems from the lack of operational national network
of laboratories in Chad.
At the present time, the northern distributor (Inodia,
France) has installed only a few (less than 20) Auto40 flow
cytometers in sub-Saharan Africa. Thus, the Auto40 flow
cytometers implemented in Chad represent more than
one-third of the analyzers installed in Africa by Inodia.
This represents, therefore, a significant business favored
by the northern distributor who is partly responsible for:
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ies of health care centers with a very low activity; b)
choosing the most expensive reagents poorly adapted for
routine use in some sites; and lastly c) using expensive
sheath fluid recycling cassettes in the provincial laborator-
ies to overcome the problems of disposing clean water.
These cassettes have been designed for autonomous usage
in Auto40 flow cytometer in military vehicles (in case of
biological war), and appear oversized and ill-adapted in
the context of Chad. Indeed, it is always possible to supply
the provinces with bottled distilled water or to produce it
locally. It would be catastrophic for Chad if the distributor
or manufacturer declared bankruptcy because the re-
sulting interruption of reagents delivery and maintenance
of Auto40 cytometers.
Collectively, the Auto40 flow cytometer, which origin-
ally had been designed for military use, is actually a reli-
able and robust analyzer. The version conceived for CD4
T cells counting in resource-limited settings provides
correct and reproducible results, in terms of both abso-
lute values and percentages. However, the costs of the
cytometer and the consumables (notably sheath fluid re-
cycling cassettes) and the contractual maintenance are
elevated. The high functional capacity of the cytometer
(150 samples per day), as well as its possibility for open
use for several types of analyses other than the quantifi-
cation of CD4 T cells, is possible in only a limited num-
ber of reference laboratories. Compared to other systems
of CD4 T cells counting designed for resource-limited
countries [9], it appears that the Auto40 flow cytometer
is most suitable for use in reference laboratories (level 1)
and possibly in district laboratories (level 2) if their clin-
ical volume is sufficient. Other systems of CD4 T cells
counting, such as the recently proposed POC systems
[9], should be selected in remote laboratories like those
of many health care centers. Another use for the Auto40
flow cytometer could be the enumeration of CD4 T cells
within mobile therapeutic units [22]. However, although
the mobile unit concept of HIV infection diagnosis and
treatment involving community health workers would be
particularly adapted for isolated populations living in re-
mote villages, as previously shown in Cameroon [32],
the Chad health care system has not yet been capable
of implementing a coherent program of “mobile” health
care for decentralization. Finally, the Auto40 analyzer
could be a reference flow cytometer allowing external
quality control, thus fulfilling some of the objectives of
the national laboratory network.
Conclusion
In conclusion, the simplified, single-platform, volumetric
Auto40 flow cytometer is a reliable alternative flow cyto-
meter for CD4 T lymphocyte enumeration which can be
used in routine immunological monitoring in resource-constrained settings like in Chad. In addition, our observa-
tions suggest that a CD4 T cell analyzer should be chosen
carefully according to the needs of each care site, and the
choice of analyzer should take into account the environ-
mental conditions and the necessity for decentralization.
Thus, an Auto40 mini flow cytometer is not suitable for
all laboratories as it is clearly oversized and ultimately very
expensive. According to our field experience and the
present evaluation, we recommend its usage mainly in ref-
erence laboratories (level 1) and in district laboratories
(level 2) if the clinical activities at these sites are sufficient,
but not in laboratories of health care centres (level 3). As
there is now a large selection of CD4 T cell counters for
resource-limited countries, the equipment needs for CD4
T cell analyzers nationwide must be clear to several manu-
facturers so that they are encouraged to offer complemen-
tary materials adapted to a limited number (2 to 3) of
health care sites.
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